fda warns semaglutide Novo Nordisk of unreported GLP-1 side effects FDA Warns About Compounded Versions

- IGF-1 (trial data suggests no meaningful change

There were over a dozen abstracts at the ASCO Annual Meeting reporting GLP-1 benefit in multiple cancers, says Elizabeth McDonald, MD, PhD, a professor of radiology and breast cancer researcher at the Hospital of the University of Pennsylvania in Philadelphia

Yes, some doctors have their own personal preferences and feelings towards using drugs for weight loss, and this can cause some doctors to tell their patients to exercise and eat healthier instead of recommending semaglutides for weigh loss

Achieving lasting weight loss and metabolic health is deeply rewarding but requires commitment

Guidelines for safe medication disposal